These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 37324951)

  • 1. TLR9 and STING agonists cooperatively boost the immune response to SARS-CoV-2 RBD vaccine through an increased germinal center B cell response and reshaped T helper responses.
    Yang JX; Tseng JC; Tien CF; Lee CY; Liu YL; Lin JJ; Tsai PJ; Liao HC; Liu SJ; Su YW; Hsu LC; Chen JK; Huang MH; Yu GY; Chuang TH
    Int J Biol Sci; 2023; 19(9):2897-2913. PubMed ID: 37324951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor-binding domain-based SARS-CoV-2 vaccine adjuvanted with cyclic di-adenosine monophosphate enhances humoral and cellular immunity in mice.
    Germanó MJ; Giai C; Cargnelutti DE; Colombo MI; Blanco S; Konigheim B; Spinsanti L; Aguilar J; Gallego S; Valdez HA; Mackern-Oberti JP; Sanchez MV
    J Med Virol; 2023 Feb; 95(2):e28584. PubMed ID: 36794675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine.
    Atalis A; Keenum MC; Pandey B; Beach A; Pradhan P; Vantucci C; O'Farrell L; Noel R; Jain R; Hosten J; Smith C; Kramer L; Jimenez A; Ochoa MA; Frey D; Roy K
    J Control Release; 2022 Jul; 347():476-488. PubMed ID: 35577151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of Toll-like receptor agonists on the immunogenicity of MVA-SARS-2-S vaccine after intranasal administration in mice.
    Do KTH; Willenzon S; Ristenpart J; Janssen A; Volz A; Sutter G; Förster R; Bošnjak B
    Front Cell Infect Microbiol; 2023; 13():1259822. PubMed ID: 37854858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN.
    Temizoz B; Kuroda E; Ohata K; Jounai N; Ozasa K; Kobiyama K; Aoshi T; Ishii KJ
    Eur J Immunol; 2015 Apr; 45(4):1159-69. PubMed ID: 25529558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus.
    Oberemok VV; Laikova KV; Yurchenko KA; Marochkin NA; Fomochkina II; Kubyshkin AV
    Inflamm Res; 2020 Sep; 69(9):801-812. PubMed ID: 32656668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Boosting the immune response in COVID-19 vaccines via an Alum:CpG complex adjuvant.
    Ji J; Tang T; Zhu M; Wu Z; Zhang J; Shi D; Zhu L; Zhang X; Lu X; Chen L; Yao H
    Antiviral Res; 2024 Sep; 229():105954. PubMed ID: 38964615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The STING activator c-di-AMP exerts superior adjuvant properties than the formulation poly(I:C)/CpG after subcutaneous vaccination with soluble protein antigen or DEC-205-mediated antigen targeting to dendritic cells.
    Volckmar J; Knop L; Stegemann-Koniszewski S; Schulze K; Ebensen T; Guzmán CA; Bruder D
    Vaccine; 2019 Aug; 37(35):4963-4974. PubMed ID: 31320219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CpG in Combination with an Inhibitor of Notch Signaling Suppresses Formalin-Inactivated Respiratory Syncytial Virus-Enhanced Airway Hyperresponsiveness and Inflammation by Inhibiting Th17 Memory Responses and Promoting Tissue-Resident Memory Cells in Lungs.
    Zhang L; Li H; Hai Y; Yin W; Li W; Zheng B; Du X; Li N; Zhang Z; Deng Y; Zeng R; Wei L
    J Virol; 2017 May; 91(10):. PubMed ID: 28275186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoparticle-Conjugated Toll-Like Receptor 9 Agonists Improve the Potency, Durability, and Breadth of COVID-19 Vaccines.
    Ou BS; Baillet J; Picece VCTM; Gale EC; Powell AE; Saouaf OM; Yan J; Nejatfard A; Lopez Hernandez H; Appel EA
    ACS Nano; 2024 Jan; 18(4):3214-3233. PubMed ID: 38215338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic effect of dual targeting vaccine adjuvant with aminated β-glucan and CpG-oligodeoxynucleotides for both humoral and cellular immune responses.
    Jin JW; Tang SQ; Rong MZ; Zhang MQ
    Acta Biomater; 2018 Sep; 78():211-223. PubMed ID: 30098441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell-dependent antigen adjuvanted with DOTAP-CpG-B but not DOTAP-CpG-A induces robust germinal center responses and high affinity antibodies in mice.
    Akkaya M; Akkaya B; Sheehan PW; Miozzo P; Pena M; Qi CF; Manzella-Lapeira J; Bolland S; Pierce SK
    Eur J Immunol; 2017 Nov; 47(11):1890-1899. PubMed ID: 28762497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pam2CSK4-adjuvanted SARS-CoV-2 RBD nanoparticle vaccine induces robust humoral and cellular immune responses.
    Qiao Y; Zhan Y; Zhang Y; Deng J; Chen A; Liu B; Zhang Y; Pan T; Zhang W; Zhang H; He X
    Front Immunol; 2022; 13():992062. PubMed ID: 36569949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants.
    Bajoria S; Kaur K; Kumru OS; Van Slyke G; Doering J; Novak H; Rodriguez Aponte SA; Dalvie NC; Naranjo CA; Johnston RS; Silverman JM; Kleanthous H; Love JC; Mantis NJ; Joshi SB; Volkin DB
    Hum Vaccin Immunother; 2022 Nov; 18(5):2079346. PubMed ID: 35666264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TLR9 plus STING Agonist Adjuvant Combination Induces Potent Neopeptide T Cell Immunity and Improves Immune Checkpoint Blockade Efficacy in a Tumor Model.
    Castro Eiro MD; Hioki K; Li L; Wilmsen MEP; Kiernan CH; Brouwers-Haspels I; van Meurs M; Zhao M; de Wit H; Grashof DGB; van de Werken HJG; Mueller YM; Schliehe C; Temizoz B; Kobiyama K; Ishii KJ; Katsikis PD
    J Immunol; 2024 Feb; 212(3):455-465. PubMed ID: 38063488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.
    Yu C; An M; Li M; Liu H
    Mol Pharm; 2017 Aug; 14(8):2815-2823. PubMed ID: 28686452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human In vitro Modeling Identifies Adjuvant Combinations that Unlock Antigen Cross-presentation and Promote T-helper 1 Development in Newborns, Adults and Elders.
    Thomas S; Pak J; Doss-Gollin S; Ryff K; Beijnen E; Pedersen GK; Christensen D; Levy O; van Haren SD
    J Mol Biol; 2024 Feb; 436(4):168446. PubMed ID: 38242283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
    Richmond P; Hatchuel L; Dong M; Ma B; Hu B; Smolenov I; Li P; Liang P; Han HH; Liang J; Clemens R
    Lancet; 2021 Feb; 397(10275):682-694. PubMed ID: 33524311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toll-like receptor agonists as adjuvants for inactivated porcine reproductive and respiratory syndrome virus (PRRSV) vaccine.
    Vreman S; McCaffrey J; Popma-de Graaf DJ; Nauwynck H; Savelkoul HFJ; Moore A; Rebel JMJ; Stockhofe-Zurwieden N
    Vet Immunol Immunopathol; 2019 Jun; 212():27-37. PubMed ID: 31213249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.